# Melanotan I Research Guide: Identity, Literature, Analysis and Documentation

> Markdown copy of https://starbio.org/melanotan-i-research-guide/ for language models and reading tools. The web page is the reference version: cite that address. Page last updated November 12, 2026.
>
> Research use only. StarBio supplies materials for in vitro laboratory research. They are not for human or veterinary use.

*Research use only. StarBio products are supplied strictly for in-vitro laboratory research by qualified professionals. They are not for human or veterinary use, not for diagnostic or therapeutic use, and have not been evaluated by the FDA. This guide covers identity, documentation and handling only. It is not usage guidance.*

Melanotan I is alpha-melanocyte-stimulating hormone with two of its thirteen residues changed: norleucine in place of methionine at position 4, and D-phenylalanine in place of the natural L form at position 7. Both changes were made for stability, and both are visible to an analyst. The same sequence is the active substance of an approved medicine, afamelanotide, which is why its literature is clinical. This page collects the identity data, the research areas that literature covers, the analytical points, and the report on file for StarBio’s lot.

## Identity

| Name | Melanotan I (afamelanotide; [Nle4, D-Phe7]-alpha-MSH) |
| --- | --- |
| Type | Synthetic linear tridecapeptide, analogue of alpha-melanocyte-stimulating hormone |
| CAS number | 75921-69-6 |
| Molecular weight | 1646.87 g/mol |
| Formula | C78H111N21O19 |
| Sequence | Ac-Ser-Tyr-Ser-Nle-Glu-His-D-Phe-Arg-Trp-Gly-Lys-Pro-Val-NH2 |
| Length | 13 (tridecapeptide) |

Melanotan I10 mg · $29.95For laboratory research use only.

[View product](https://starbio.org/product/melanotan-i/)

## Origin and history

The analogue was first described in 1980 by Tomi Sawyer, Victor Hruby, Mac Hadley and colleagues at the University of Arizona, as part of a systematic effort to find which residues of alpha-MSH could be changed to make it longer-lived. Decades later the same molecule was developed as afamelanotide and approved in the European Union in 2014 and the United States in 2019 for a rare light-sensitivity disorder, erythropoietic protoporphyria. The material StarBio supplies is a synthetic research chemical of the same sequence, sold for laboratory use only. It is not the medicine, and nothing on this page describes a use of it.

## What the literature covers

The references on file for this compound span several research areas. They are listed here as areas of study, not as results.

- **The approved medicine in erythropoietic protoporphyria.** Clinical papers and reviews from 2010 to 2021 [1, 3, 8, 9, 11].
- **Pharmacokinetics and immunogenicity.** A 2017 review of pharmacokinetics and pharmacodynamics [7] and a 2015 immunogenicity evaluation [4].
- **Other dermatology research.** A 2014 study in acne [2] and a 2021 overview of dermatologic research directions [10].
- **Formulation and stability.** A gel-forming analogue (2023) [5] and a 2026 stability study using liquid chromatography with high-resolution mass spectrometry [6].

The 2026 stability study is the reference most useful to an analyst, because it characterises the degradation products of this exact sequence.

## Analytical notes

Norleucine at position 4 removes the methionine of the natural hormone and with it the main oxidation site. It also changes the mass, so the certificate should match 1646.87 g/mol and not the mass of alpha-MSH itself. Tryptophan at position 9 remains, and it is the residue most sensitive to light and oxidation. With one tryptophan and one tyrosine the peptide absorbs at 280 nm as well as at 220 nm.

The D-phenylalanine cannot be confirmed by mass alone: a peptide with the L form at that position has an identical mass and shows only as a separate, closely eluting peak. Mass spectrometry confirms identity at a monoisotopic 823.9 for the doubly protonated molecule and 549.6 for the triply protonated one. Both ends are capped, with an acetyl group at the N-terminus and an amide at the C-terminus, and a missing cap shows as a mass 42 Da or 1 Da off.

## Storage and stability

- Lyophilized powder
- Store at -20 °C
- Protect from light
- Avoid repeated freeze-thaw cycles
- In solution: 2-8 °C, short term

## Documentation for StarBio lots

Every StarBio lot is analysed by an independent laboratory. The table lists the report on file for this compound.

| Variant | Laboratory / report | HPLC purity | Labelled / measured | Tested |  |
| --- | --- | --- | --- | --- | --- |
| Melanotan I 10 mg | Medutest WWB-MT1-7786 | 99.53% | 10 mg | Feb 20, 2026 | [report](https://starbio.org/wp-content/uploads/2026/07/coa-medutest-MT-1_10mg.webp) |

Current certificates are in the [COA Library](https://starbio.org/coa/); the [verify-lot form](https://starbio.org/verify-lot/) connects an order to its batch record.

## References

1. [An α-MSH analog in erythropoietic protoporphyria](https://pubmed.ncbi.nlm.nih.gov/25785940/). The Journal of investigative dermatology, 2015, PMID 25785940.
2. [Beneficial effects of the melanocortin analogue Nle4-D-Phe7-α-MSH in acne vulgaris](https://pubmed.ncbi.nlm.nih.gov/22845050/). Journal of the European Academy of Dermatology and Venereology : JEADV, 2014, PMID 22845050.
3. [Afamelanotide, an agonistic analog of α-melanocyte-stimulating hormone, in dermal phototoxicity of erythropoietic protoporphyria](https://pubmed.ncbi.nlm.nih.gov/21073357/). Expert opinion on investigational drugs, 2010, PMID 21073357.
4. [Evaluation of the immunogenicity of the synthetic α-melanocyte-stimulating hormone (α-MSH) analogue afamelanotide ((Nle4-D-Phe7)-α-MSH, Scenesse®) in erythropoietic protoporphyria patients by ELISA detecting both anti-afamelanotide and anti-α-MSH antibodies](https://pubmed.ncbi.nlm.nih.gov/25402764/). Skin pharmacology and physiology, 2015, PMID 25402764.
5. [A gel-forming α-MSH analog promotes lasting melanogenesis](https://pubmed.ncbi.nlm.nih.gov/37673364/). European journal of pharmacology, 2023, PMID 37673364.
6. [Investigation of the stability profile of therapeutic α-MSH analogue: Insights from liquid chromatography-high resolution mass spectrometry analysis of afamelanotide](https://pubmed.ncbi.nlm.nih.gov/41547183/). Journal of pharmaceutical and biomedical analysis, 2026, PMID 41547183.
7. [Pharmacokinetics and Pharmacodynamics of Afamelanotide and its Clinical Use in Treating Dermatologic Disorders](https://pubmed.ncbi.nlm.nih.gov/28063031/). Clinical pharmacokinetics, 2017, PMID 28063031.
8. [Afamelanotide for prevention of phototoxicity in erythropoietic protoporphyria](https://pubmed.ncbi.nlm.nih.gov/33507118/). Expert review of clinical pharmacology, 2021, PMID 33507118.
9. [Afamelanotide: A Review in Erythropoietic Protoporphyria](https://pubmed.ncbi.nlm.nih.gov/26979527/). American journal of clinical dermatology, 2016, PMID 26979527.
10. [Afamelanotide: An Orphan Drug with Potential for Broad Dermatologic Applications](https://pubmed.ncbi.nlm.nih.gov/33683075/). Journal of drugs in dermatology : JDD, 2021, PMID 33683075.
11. [Afamelanotide (CUV1647) in dermal phototoxicity of erythropoietic protoporphyria](https://pubmed.ncbi.nlm.nih.gov/25470471/). Expert review of clinical pharmacology, 2015, PMID 25470471.

Product page: [Melanotan I](https://starbio.org/product/melanotan-i/). Related guides: [Melanotan II research guide](https://starbio.org/melanotan-ii-research-guide/), [Pt 141 research guide](https://starbio.org/pt-141-research-guide/), [what 99% purity means](https://starbio.org/what-99-percent-purity-means/), [storing lyophilized peptides](https://starbio.org/storing-lyophilized-research-peptides/).

*For laboratory research use only. Not for human or veterinary use.*

Compared with related compounds: [Melanotan I vs Melanotan II vs PT-141](https://starbio.org/melanotan-i-vs-melanotan-ii-vs-pt-141/).

## Questions about Melanotan I

### What is Melanotan I?

Melanotan I is a linear melanocortin receptor agonist peptide: 13 residues (tridecapeptide), molecular weight 1646.87 g/mol, CAS number 75921-69-6. It is supplied for in vitro laboratory research only. This guide covers identity, documentation and handling, not use.

### Is Melanotan I the same as Afamelanotide, MT-I and [Nle4, D-Phe7]-alpha-MSH?

Melanotan I is also listed as Afamelanotide, MT-I and [Nle4, D-Phe7]-alpha-MSH. On a certificate or vial label, the CAS number (75921-69-6) and the sequence identify the material regardless of which name is used.

### What are the CAS number, formula and molecular weight of Melanotan I?

Melanotan I has CAS number 75921-69-6, molecular formula C78H111N21O19 and molecular weight 1646.87 g/mol. Sequence: Ac-Ser-Tyr-Ser-Nle-Glu-His-D-Phe-Arg-Trp-Gly-Lys-Pro-Val-NH2. Identity of each StarBio batch is confirmed by mass spectrometry on the laboratory report.

### Is StarBio's Melanotan I independently tested?

Yes. The current Melanotan I batch was tested by Medutest (Medutest report WWB-MT1-7786): 99.53% purity by HPLC, tested Feb 20, 2026. The report is on file in the [COA library](https://starbio.org/coa/) ([report page](https://starbio.org/coa/melanotan-i-10-mg-medutest-wwb-mt1-7786/)).

### How should Melanotan I be stored?

Lyophilized powder; Store at -20 °C; Protect from light; Avoid repeated freeze-thaw cycles; In solution: 2-8 °C, short term. StarBio ships it as sealed lyophilized powder.

### Where can I buy Melanotan I for laboratory research?

StarBio sells [Melanotan I](https://starbio.org/product/melanotan-i/) as 10 mg at $29.95, shipped tracked from Florida to all 50 US states. StarBio does not ship internationally. Buyers must be qualified researchers or institutions aged 21 or older, buying for in vitro laboratory work.

---

StarBio: https://starbio.org/ | Site summary for language models: https://starbio.org/llms.txt | Laboratory report data: https://starbio.org/coa.json
